Galectin Therapeutics Inc... (GALT)
1.24
0.01 (0.81%)
At close: Jan 30, 2025, 11:56 AM
undefined% (undefined)
| Bid | 1.24 |
| Market Cap | 77.27M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.73 |
| PE Ratio (ttm) | -1.7 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.25 |
| Volume | 77,201 |
| Avg. Volume (20D) | 738,741 |
| Open | 1.22 |
| Previous Close | 1.23 |
| Day's Range | 1.22 - 1.25 |
| 52-Week Range | 0.73 - 4.27 |
| Beta | undefined |
About GALT
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatiti...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 4, 2002
Employees 14
Stock Exchange NASDAQ
Ticker Symbol GALT
Website https://galectintherapeutics.com
Analyst Forecast
According to 1 analyst ratings, the average rating for GALT stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 787.03% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago
-48%
Galectin Therapeutics shares are trading lower aft...
Unlock content with
Pro Subscription
